Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial

Guomin Xiao^*¹ , Jing Wei² , Weiqi Yan^*³ , Weimin Wang¹ and Zhenhui Lu³

¹Department of Neurosurgery and Neurotrauma Center, Affiliated Hospital, College of Medicine, Hangzhou Normal University, Hangzhou 310015, China

²Department of Health Center, Affiliated Hospital, College of Medicine, Hangzhou Normal University, Hangzhou 310015, China

³Clinical Research Centre, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China

author email corresponding author email* Contributed equally

Critical Care 2008, 12:R61doi:10.1186/cc6887


Published:	30 April 2008

See related commentary by Vandromme et al., http://ccforum.com/content/12/3/153

Abstract

Background

Severe traumatic brain injury (TBI) has been increasing with greater incidence of injuries from traffic or sporting accidents. Although there are a number of animal models of TBI using progesterone for head injury, the effects of progesterone on neurologic outcome of acute TBI patients remain unclear. The aim of the present clinical study was to assess the longer-term efficacy of progesterone on the improvement in neurologic outcome of patients with acute severe TBI.

Methods

A total of 159 patients who arrived within 8 hours of injury with a Glasgow Coma Score ≤ 8 were enrolled in the study. A prospective, randomized, placebo-controlled trial of progesterone was conducted in the Neurotrauma Center of our teaching hospital. The patients were randomized to receive either progesterone or placebo. The primary endpoint was the Glasgow Outcome Scale score 3 months after brain injury. Secondary efficacy endpoints included the modified Functional Independence Measure score and mortality. In a follow-up protocol at 6 months, the Glasgow Outcome Scale and the modified Functional Independence Measure scores were again determined.

Results

Of the 159 patients randomized, 82 received progesterone and 77 received placebo. The demographic characteristics, the mechanism of injury, and the time of treatment were compared for the two groups. After 3 months and 6 months of treatment, the dichotomized Glasgow Outcome Scale score analysis exhibited more favorable outcomes among the patients who were given progesterone compared with the control individuals (P = 0.034 and P = 0.048, respectively). The modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up (P < 0.05 and P < 0.01). The mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05). The mean intracranial pressure values 72 hours and 7 days after injury were lower in the progesterone group than in the placebo group, but there was no statistical significance between the two groups (P > 0.05). Instances of complications and adverse events associated with the administration of progesterone were not found.

Conclusion

Our data suggest that acute severe TBI patients with administration of progesterone hold improved neurologic outcomes for up to 6 months. These results provide information important for further large and multicenter clinical trials on progesterone as a promising neuroprotective drug.

Trial Registration

ACTRN12607000545460.